Document is current
Any future updates will be listed below
-
Authors
Merk, Daniel J. https://orcid.org/0000-0003-2935-6919
Tsiami, Foteini https://orcid.org/0009-0001-6070-0434
Hirsch, Sophie
Walter, Bianca https://orcid.org/0000-0001-9734-4843
Haeusser, Lara A. https://orcid.org/0000-0002-3288-4280
Maile, Jens D.
Stahl, Aaron https://orcid.org/0000-0003-3616-9564
Jarboui, Mohamed A. https://orcid.org/0000-0002-5203-235X
Lechado-Terradas, Anna https://orcid.org/0000-0003-2650-965X
Klose, Franziska
Babaei, Sepideh https://orcid.org/0000-0002-5957-6907
Admard, Jakob https://orcid.org/0000-0003-0466-582X
Casadei, Nicolas https://orcid.org/0000-0003-2209-0580
Roggia, Cristiana
Spohn, Michael
Schittenhelm, Jens https://orcid.org/0000-0002-9168-6209
Singer, Stephan
Schüller, Ulrich https://orcid.org/0000-0002-8731-1121
Piccioni, Federica https://orcid.org/0000-0003-1210-3210
Persky, Nicole S. https://orcid.org/0000-0002-9948-2761
Claassen, Manfred https://orcid.org/0000-0002-4583-9083
Tatagiba, Marcos https://orcid.org/0000-0002-1627-9937
Kahle, Philipp J. https://orcid.org/0000-0002-8587-1731
Root, David E. https://orcid.org/0000-0001-5122-861X
Templin, Markus https://orcid.org/0000-0002-6569-6489
Tabatabai, Ghazaleh https://orcid.org/0000-0002-3542-8782
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (496706655)
Else Kröner-Fresenius-Stiftung (GSO/EKFS 5)
Else Kröner-Fresenius-Stiftung (2015_kolleg_14)
Adolf Leuze Stiftung
Medizinische Fakultät Tübingen (Demonstratorprojekt Personalisierte Medizin)
Deutsche Forschungsgemeinschaft (SCHU 2442/7-1)
Deutsche Forschungsgemeinschaft (INST 37/1049-1)
Deutsche Forschungsgemeinschaft (Cluster of Excellence, EXC 2180, 390900677)
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 18 November 2024
First Online: 2 December 2024
Declarations
:
: All animal experiments were approved by the Regierungspräsidium Tübingen (N 09/20 G and N 11/20 M). All experiments were conducted in accordance with the animal law. Animals were closely monitored. For reporting, we followed the ARRIVE guidelines (version 2.0).
: Not applicable.
: GT has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as steering committee member in non-interventional trials (Bayer, Novocure), as a speaker (Novocure, Servier), and financial compensation for all these activities was provided as institutional funding to the University Hospital Tübingen. FP has been affiliated with the Broad Institute while contributing to this study, but is now working at Merck Research Laboratories, Cambridge, USA. This new affiliation does not constitute any financial interest or any other engulfment associated with this study.
